Abstract: A silicone oil-based anhydrous cosmetic or dermatological anhydrous composition having a homogeneous fatty phase wherein said fatty phase contains a silicone oil having the formula ##STR1## wherein R represents alkyl having 1 to 30 carbon atoms, aryl or aralkyl,n represents a whole number between 0 and 100, andm represents a whole number between 0 and 100, provided that the sum of n+m is between 1 and 100; and(ii) a wax in an amount ranging from 3 to 50 percent by weight based on the total weight of said fatty phase having a melting point between 50.degree. and 135.degree. C., comprising at least polymer having a molecular weight between 200 and 1,500 and selected from ethylene homopolymers and copolymers, and a monomer having the formula:CH.sub.2 .dbd.CH--R' (II)whereinR' represents alkyl having 1 to 30 carbon atoms, aryl or aralkyl.

Abstract: A process for preparing a composition suitable for topical application to human skin is disclosed. The process comprises mixing particles of metallic oxide dispersed in oil and having a primary particle size less than 0.2 micrometer with one or more emulsifiers, an aqueous phase and a hydrophilic organic sunscreen so as to prepare an emulsion. The composition contains up to 10 percent by weight metallic oxide and up to 7 percent by weight hydrophilic organic sunscreen. The emulsions are useful as sunscreen compositions, skin protectants, moisturisers, and after-sun lotions. The measured Sun Protection Factor for a composition of the invention is considerably higher than would be expected from a knowledge of the individual UV absorbing characteristics of the metallic oxide and the hydrophilic organic sunscreen.

Abstract: N-Acyl-.alpha.-aminocarboxylic acid derivatives of the formula ##STR1## wherein L, R' to R"' and Q have the significance given in the description, can be used for the treatment or prophylaxis of illnesses which are caused by the binding of adhesive proteins to blood platelets and by blood platelet aggregation and cell-cell adhesion. They are manufactured by cleaving off protecting groups in corresponding protected compounds or by converting the cyano group into the amidino group in corresponding nitriles.

Abstract: The use of sulfuric monoesters of the formulae (I) and (II)R.sup.1 --O--(CH.sub.2 O).sub.n --SO.sub.3 .sup.- M.sup.+ (I)R.sup.1 --CO--NR.sup.2 --(CH.sub.2 O)(.sub.n+1)--SO.sub.3 .sup.- M.sup.+ (II)in whichR.sup.1 is a straight-chain or branched alkyl group of 10 to 24 carbon atoms,R.sup.2 is a hydrogen atom or a C.sub.1 -C.sub.6 -alkyl group,M.sup.+ is a hydrogen ion, an alkali metal ion, 1/2 an alkaline earth metal ion, or an ammonium ion of the formula N.sup.+ R.sup.3 R.sup.4 R.sup.5 R.sup.6, where the substituents R.sup.3, R.sup.4, R.sup.5 and R.sup.6 independently of one another are each hydrogen atoms or C.sub.1 -C.sub.6 -alkyl groups, which alkyl groups can be substituted by 1 to 3 hydroxyl groups, andn is a number from 0 to 4; or of a mixture of at least two sulfuric monoesters of the formulae (I) and/or (II),for preparing surface-treated pigments from the classes of the quinacridones and dioxazines.

Abstract: Heterocyclic thrombin inhibitors are provided which have the structure ##STR1## wherein n, R, R.sup.1, R.sup.2, R.sup.3, G, G.sub.x, R.sup.6', Ra, Xa, R.sup.6, Rb, R.sub.3, p, Q, A and R.sup.4 are as defined herein.

Abstract: Heterocyclic thrombin inhibitors are provided which have the structure ##STR1## wherein n, R, R.sup.1, R.sup.2, R.sup.3, G, G.sub.x, R.sup.6 ', Ra, Xa, R.sup.6, Rb, R.sub.3, p, Q, A and R.sup.4 are as defined herein.

Abstract: Compounds of formula (I): ##STR1## ?wherein: X represents an unsubstituted or substituted indolyl, indolinyl, azaindolyl, azaindolinyl, imidazopyridyl or imidazopyrimidinyl group; Y represents an oxygen or sulfur atom; Z represents a 2,4-dioxo-thiazolidin-5-ylidenylmethyl, 2,4-dioxothiazolidin-5-ylmethyl, 2,4-dioxooxazolidin-5-ylmethyl, 3,5-dioxooxadiazolidin-2-ylmethyl or N-hydroxyureidomethyl group; R represents a hydrogen atom, an alkyl group, an alkoxy group, a halogen atom, a hydroxy group, a nitro group, an aralkyl group or a unsubstituted or substituted amino group; and m is an integer of from 1 to 5! have hypoglycemic and anti-diabetic activities. Disclosed also are intermediate compounds for the preparation of compounds of formula I.

Abstract: There are provided novel antitussive agents different from existing antitussive agents or those under development. Antitussive agents containing morphinan derivatives represented by compound 6: ##STR1## or pharmacologically acceptable acid-addition salts thereof and those derivatives or their salts as effective components.The antitussive agents according to the present invention have strong antitussive effects as highly selective .kappa.-opioid agonists, and may thus be applied as useful antitussive agents in the prophylaxis and treatment of coughing in a patient in need thereof.

Abstract: Cyclohexane derivatives, process for their preparation, and the use of the compounds for the treatment of diseasesCyclohexane derivatives of the formula I ##STR1## wherein R.sup.2, R.sup.4 and R.sup.5 have the given meanings and a process for their preparation are described. The compounds have useful pharmacological properties and can therefore be used as pharmaceuticals.

Abstract: Disclosed are N,N'-bis(quinolin-4-yl)diamine derivatives of general formula I wherein R.sup.1 signifies halogen or trifluoromethyl, R.sup.2 signifies hydrogen or halogen, A signifies cyclohexane-1,3-diyl, 2-methyl-cyclohexane-1,3-diyl, cyclohexane-1,4-diyl, dicyclohexylmethane-4,4'-diyl, cyclopentane-1,3-diyl, phenylene-1,4, phenylene-1,3 and phenylene-1,2; n is 1 or 2; m is 1 or 2, as well as their pharmaceutically acceptable salts. These products are useful as agents for preventing malaria and for treating it, especially where the pathogens are resistant to chloroquine.

Abstract: The present invention relates to 4-(6-fluoro-1,2-benzisoxazolyl)-1-piperidinyl-propoxy-chromen-4-one derivatives having the formula (I): ##STR1## wherein R is hydrogen or alkyl having 1 to 4 carbon atoms optionally substituted by hydroxyl, as well as their pharmaceutically acceptable addition salts, which are useful in the treatment of psychosis, schizophrenia and anxiety.

Abstract: The invention relates to biphenyl derivatives of general formula ##STR1## wherein A to E and X are defined as in claim 1, the stereoisomers thereof, including their mixtures and the salts thereof, particularly the physiologically acceptable salts thereof with inorganic or organic acids or bases, which have valuable properties, preferably aggregation-inhibiting effects, pharmaceutical compositions containing these compounds and processes for preparing them.

Abstract: The present invention relates to certain reconstituted wax esters, prepared by the reaction of a silicone polymer and a natural high molecular wax ester selected from the group consisting of beeswax, candelillia, and carnauba wax. These materials are useful in preparation of cosmetic products where their ability to couple organic silicone and other components into a uniform mass is unsurpassed. One major area for the use of these materials is in lipsticks. In addition they are useful in antiperspirants and other formulations which contain both oils and silicones.

Abstract: The present invention relates to compounds of formula: ##STR1## which are agonists of cholecystokinin receptors and pharmaceutical compositions containing them.

Abstract: An industrially advantageous process for producing 5,7-dichloro-4-hydroxyquinoline (DCHQ) useful as an intermediate for agrohorticultural bactericides. The process comprises (i) hydrolyzing 3-cyano- or 3-ethoxycarbonyl-5,7-dichloro-4-hydroxyquinoline into 5,7-dichloro-3-carboxy-4-hydroxyquinoline (DCQA) in the presence of hydrochloric, sulfuric or phosphoric acid and (ii) decarboxylating the formed DCQA into DCHQ in the presence of sulfuric or phosphoric acid. In particular, this process comprises continuously conducting the hydrolysis of 5,7-dichloro-3-ethoxycarbonyl-4-hydroxyquinoline and the decarboxylation of the hydrolyzate in the presence of sulfuric acid having a specified concentration. The invention also relates to a process for producing DCQA by hydrolyzing 3-cyano- or 3-ethoxycarbonyl-5,7-dichloro-4-hydroxyquinoline in the presence of hydrochloric, sulfuric or phosphoric acid and a process for producing DCHQ by decarboxylating DCQA in the presence of sulfuric or phosphoric acid.

Abstract: A compound of Formula I, which is named {5R*-?6R*, 7S*, 8R*, 9R*, 12S*, 16S*, 18S*, 19S*, (13E)!} 4, 7, 19-trihydroxy-2, 6, 8, 12, 12, 14, 16, 18-heptamethyl-6, 7, 8, 9, 10, 11, 12, 15, 16, 17, 18, 19-dodecahydro-1, 19:5, 9-diepoxybenzocyclooctadecen-3 (5H)-one, and which is useful in inhibiting bone resorption, and treating and inhibiting osteoporosis.

Abstract: The present invention provides compounds of formula I: ##STR1## wherein X is --O-- or --S--,Y is --O--, --S--, --CH.sub.2 --, --CH.sub.2 CH.sub.2 --, --CH.dbd.CH--, or --NR.sup.5 --;R.sup.1, R.sup.2, and R.sup.3 are each independently --H, --OH, --O(C.sub.1 -C.sub.4 alkyl), --OCOC.sub.6 H.sub.5, --OCO(C.sub.1 -C.sub.6 alkyl), --OSO.sub.2 (C.sub.4 -C.sub.6 alkyl), --OSO.sub.2 CF.sub.3, Cl, or F;n is 1 or 2;W is CH.sub.2 or C.dbd.O;R.sup.4 is 1-piperidinyl, 2-oxo-1-piperidinyl, 1-pyrrolidinyl, methyl-1-pyrrolidinyl, dimethyl-1-pyrrolidinyl, 2-oxo-1-pyrrolidinyl, 4-morpholino, dimethylamino, diethylamino, or 1-hexamethyleneimino;R.sup.5 is C.sub.1 -C.sub.3 alkyl, --COC.sub.6 H.sub.5, --CO(C.sub.1 -C.sub.6 alkyl), --C(O)OC.sub.6 H.sub.5, --C(O)O(C.sub.1 -C.sub.6 alkyl), --SO.sub.2 (C.sub.1 -C.sub.6 alkyl), --SO.sub.2 C.sub.6 H.sub.5, or --SO.sub.2 CF.sub.3 ;or a pharmaceutically acceptable salt or solvate thereof.

Abstract: Compounds of formula (I): ##STR1## in which: n represents 1 or 2,R.sub.1 represents hydrogen or alkyl, benzyl, acetyl, benzoyl, allyl, pyridinecarbonyl, pyridinemethyl, acylaminoalkyl (optionally substituted), pyridineaminocarbonyl, phthalimidoalkyl, thiochromanyloxyalkyl or (benzodioxanyloxy)alkyl,R.sub.2, R.sub.3 or R.sub.4, which may be identical or different, represent hydrogen or halogen or alkyl, alkoxy, hydroxyl, acetyl, aminocarbonyl, aminomethyl, cyano, nitro, amino, phenyl (which may or may not be substituted), furyl, pyridinyl, thienyl or pyridyl, or alternatively, when they are located on adjacent carbons, R.sub.2 and R.sub.3 form, with the carbon atoms which bear them, a furan or phenyl ring,the isomers thereof and the addition salts thereof with a pharmaceutically acceptable acid, and medicinal products containing the same are useful for the treatment of diseases requiring a ligand to the 5-HT.sub.2C receptors.

Abstract: A series of novel pyrrolo?2,1-a!isoquinoline dyes has been prepared using readily available starting materials via a simple synthetic pathway. These dyes have narrow absorption bands in the range of 500-900 nm. Those that absorb in the near-infrared region (700-1400 nm) lack significant absorption in the 300-400 nm ultraviolet region of the spectrum; this is an advantage for use in an applications such as imaging setting film. In addition, the greater thermal and chemical stability of these dyes in comparison to their indolizine analogues should be valuable in many applications.

Abstract: The present invention relates to novel substituted benzylamino nitrogen containing non-aromatic heterocycles and, specifically, to compounds of the formula ##STR1## wherein W, R.sup.1, R.sup.2, R.sup.3 and A are as defined in the specification, and to intermediates used in the synthesis of such compounds. The novel compounds of formula I are useful in the treatment of inflammatory and central nervous system disorders, as well as other disorders.